Comparison of Two Different Intravitreal Injection Techniques
Harvey S Uy, Jose Carlo M Artiaga, Harvey S Uy, Jose Carlo M Artiaga
Abstract
Objective: To compare the effectiveness, procedure time and safety outcomes of two different intravitreal injections (IVI) techniques.
Methods: This was a prospective, single-center, randomized clinical trial of 200 adult eyes receiving intravitreal medications for various indications. Eyes were assigned (1:1) to undergo IVI using either an intravitreal injection guide (IIG) (n= 100) or conventional dual blade speculum plus surgical caliper (DBS) (n=100). All IVI were administered using a 30-gauge needle placed 4 mm posterior to the inferior limbus. The main outcome measures were rate of successful IVI administration, procedure time (seconds) as measured by a stopwatch from application to removal of IIG or DBS, patient preference for IVI technique and adverse events.
Results: The two groups were similar in terms of mean age (P=0.398), laterality (P=0.671), indication for treatment (P=0.175) and medication type (P=0.489). All IVI procedures were successfully completed in both groups. The mean procedure time was shorter using the IIG (9.94 ± 2.87 seconds) versus DBS (21.85 ± 7.25 seconds) technique (P ≤ 0.01). The incidence of post-injection subconjunctival hemorrhage was higher when the DBS was applied (OR = 2.35, 95% CI = 1.22-4.53). Patients with previous history of IVI preferred the IIG over the DBS. No other injection-related adverse events were observed in both groups.
Conclusion: DBS and IIG techniques are similarly effective and safe for the administration of intravitreal medications. The IIG appears to significantly reduce procedure time, be associated with a lower incidence of subconjunctival hemorrhage and engender better patient acceptance.
Clinical trial registration: ClinicalTrials.gov (NCT04455399).
Keywords: aflibercept; anti-vascular endothelial growth factor; bevacizumab; intravitreal injection; intravitreal injection guide; ranibizumab.
Conflict of interest statement
The authors report no conflicts of interest in this work.
© 2021 Uy and Artiaga.
Figures
References
- Lai TY, Liu S, Das S, Lam DS. Intravitreal Injection–Technique and Safety. Asia Pac J Ophthalmol. 2015;4(6):321–328. doi:10.1097/APO.0000000000000146
- Friedman DS, O’Colmain BJ, Munoz B, et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572.
- Prenner JL, Halperin LS, Rycroft C, et al. Disease Burden in the Treatment of Age Related Macular Degeneration: findings From a Time-and-Motion Study. Am J Ophthalmol. 2015;160(4):725–731. doi:10.1016/j.ajo.2015.06.023
- Michelotti MM, Abugreen S, Kelly SP, et al. Transformational change: nurses substituting for ophthalmologists for intravitreal injections - a quality-improvement report. Clin Ophthalmol. 2014;8:755–761. doi:10.2147/OPTH.S59982
- Rahimy E, Fineman MS, Regillo CD, et al. Speculum versus Bimanual Lid Retraction during Intravitreal Injection. Ophthalmology. 2015;122(8):1729–1730. doi:10.1016/j.ophtha.2015.02.001
- Alattas K. Patients’ tolerance of bimanual lid retraction versus a metal speculum for intravitreal injections. Clin Ophthalmol. 2016;10:1719–1721. doi:10.2147/OPTH.S113326
- Fineman MS, Hsu J, Spirn MJ, Kaiser RS. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33(9):1968–1970. doi:10.1097/IAE.0b013e318287da92
- Mason RW. Use of a Desmarres retractor for upper lid and lash isolation during intravitreal injections. Retina. 2013;33(10):2175–2176. doi:10.1097/IAE.0b013e3182999a1b
- Shrier EM. Cotton-tip applicator lid retraction technique for controlled intravitreal injection. Retina. 2014;34(6):1244–1246. doi:10.1097/IAE.0000000000000219
- Ratnarajan G, Nath R, Appaswamy S, Watson SL. Intravitreal injections using a novel conjunctival mould: a comparison with a conventional technique. Br J Ophthalmol. 2013;97(4):395–397. doi:10.1136/bjophthalmol-2012-302155
- Han DP, McKenney KC, Kim JE, Weinberg DV, Musch DC, Singh RS. CLINICAL EVALUATION OF THE RAPID ACCESS VITREAL INJECTION GUIDE: a Handheld Instrument for Assisting Intravitreal Injections. Retina. 2017;37(4):778–781. doi:10.1097/IAE.0000000000001229
- Watanabe K, Masafumi U, Mohamed YH, et al. Safety of Intravitreal Injection Guide. J Vitreoretin Dis. 2017;2(1):26–31. doi:10.1177/2474126417728622
- Soh YQ, Chiam NPY, Tsai ASH, et al. Intravitreal injection with a conjunctival injection device: a single-center experience. Trans Vis Sci Tech. 2020;9(8):28. doi:10.1167/tvst.9.8.28
- Waqar S. Comment on: optimisation of intravitreal injection technique using a Barraquer speculum with solid flat blade and finger stabilisation. Eye. 2019;33(3):512. doi:10.1038/s41433-018-0248-3
- Waqar S, Ayaz A, Karamat I, et al. A novel device for rapid, safe and precise delivery of intravitreal injections. BMJ Innov. 2019;5(1):8–12. doi:10.1136/bmjinnov-2018-000337
- U.S. Food and Drug Administration. CFR – code of Federal Regulations Title 21. Available from: . Accessed March23, 2020.
- Tailor R, Beasley R, Yang Y, Narendran N. Evaluation of patients’ experiences at different stages of the intravitreal injection procedure - what can be improved? Clin Ophthalmol. 2011;5:1499–1502. doi:10.2147/OPTH.S24358
- McCannel C. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661. doi:10.1097/IAE.0b013e31820a67e4
- Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787–794. doi:10.1038/eye.2013.107
- Haddock LJ, Ramsey DJ, Young LH. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications. Semin Ophthalmol. 2014;29(5–6):257–262. doi:10.3109/08820538.2014.959616
- Sigford DK, Reddy S, Mollineaux C, et al. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol. 2015;9:773–781. doi:10.2147/OPTH.S77067
- Baneke AJ, Vakros G, Sharma V, Wong SC. Bleb-related endophthalmitis after use of the InVitria injection guide. Retin Cases Brief Rep. 2020;14(1):33–34. doi:10.1097/ICB.0000000000000631
- Grzybowski A, Told R, Sacu S, et al.. 2018 update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181–193. doi:10.1159/000486145.
- Ullrich F, Michels S, Lehmann D, Pieters RS, Becker M, Nelson BJ. Assistive device for efficient intravitreal injections. Ophthalmic Surg Lasers Imaging Retina. 2016;47(8):752–762. doi:10.3928/23258160-20160808-09
Source: PubMed